Drug Literature Cases Raise First Amendment Issues
This article was originally published in The Tan Sheet
Executive Summary
Litigation over the dissemination of scientific information at odds with FDA's instructions could define how the right to freedom of speech applies to marketing food and drug products.
You may also be interested in...
FDA Warning Letters Do Not Prove Wrongdoing, Appeals Court Finds
A state appeals court ruled that FDA warning letters are informal and advisory notifications and thus cannot be the basis of a finding that Johnson & Johnson made false and misleading statements to health care providers about Risperdal (risperidone) and Duragesic (fentanyl).
Selenium Claim Ruling Forces FDA's Hand, May Clear Path For More QHCs
A court decision obligating FDA to reconsider a slate of qualified health claims for selenium could compel the agency to allow more QHCs for dietary supplements
Coalition Pushes Congress On OTC Purchases With Health Savings Accounts
The Health Choices Coalition sent letters urging House and Senate members to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.